Update to MA schedule

You are here

Lyon, 8 June 2016 - Amoéba today announced a revised schedule for its acquisition of provisional MA. The assessment report required to obtain the provisional MA for France and Europe, initially scheduled to be delivered in May 2016, should be available during the second half of 2016. As a consequence, the company has indicated that its projected sales in France and Europe should be shifted back by a half-year relative to the schedule announced. The first sales under the provisional MA are therefore expected at the start of 2017. The company has sufficient treasury to cope with this delay. Fabrice PLASSON declares: “We will take advantage of this delay of our plans by a few months to continue optimising our industrial yields. This will allow Amoéba to anticipate the strong demand expected in 2017 from our many European clients who are already waiting to be able to use our biological solution.

 

Related Posts